Observational analysis shows TPO receptor agonists improved platelet counts in multiple myeloma patients, suggesting better management of persistent thrombocytopenia.
Key Points
Median platelet counts rose significantly from 14×10⁹/L to 41×10⁹/L during TPO receptor agonist treatment, showing effective recovery for some patients.
Logistic regression identified ferritin as an independent risk factor for persistent thrombocytopenia, with univariate analysis highlighting inflammatory markers.
Bone marrow biopsies revealed hypercellularity with megakaryocytic presence post-treatment, indicating hematologic recovery potential.
Patients treated with TPO-RAs had better platelet maintenance than those on supportive therapy alone, emphasizing the importance of TPO receptor agonists.